Type 1 interferon regulators as prognostic markers and predictors of therapeutic response in triple negative breast cancer

Lead researcher

Dr Belinda Parker, A/Prof Phil Darcy

Institution

La Trobe University

Years funded

2017-2019

This project explores the importance of an immune pathway in response to current and emerging breast cancer therapies. The results may lead to individualised treatment for patients with triple negative breast cancers.

Funding Body

Cancer Council Research Grant

Funding

$96,378 in 2017, $97,778 in 2018 and $99,778 in 2019

Updated: